Actively Recruiting
Investigation of Date Consumption Effects on Hedonic Hunger and Appetite Hormones in Adults with Type 2 Diabetes
Led by Hacettepe University · Updated on 2025-02-13
64
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of consuming dates on hedonic hunger and appetite-related hormones in adults with Type 2 diabetes. This randomized controlled clinical trial aims to determine whether eating three dates daily can reduce hedonic hunger and influence levels of hormones such as Ghrelin, GLP-1, and GIP. The study also examines impacts on insulin resistance, blood sugar control, and cholesterol levels in individuals aged 19 to 50 years with Type 2 diabetes. Participants are randomly assigned to either an intervention group or a control group. Those in the intervention group consume three Baghdad dates daily at breakfast, while the control group avoids date consumption. The study spans 12 weeks with three interviews at the start, 6 weeks, and 12 weeks. Dates are provided in two 6-week supplies, and participants track their date intake using weekly recording sheets, supported by regular reminders. Throughout the study, participants undergo interviews and complete questionnaires assessing hunger, food intake, and physical activity. Anthropometric measurements like height, weight, and body composition are taken at baseline, 6 weeks, and 12 weeks. Blood samples at the start and end of the study measure fasting glucose, insulin, HbA1c, lipid profiles, and hormone levels. Additional blood glucose monitoring occurs at all three visits. Researchers will analyze changes in appetite hormones and hedonic hunger over the 3-month period.
CONDITIONS
Brief Title
Investigation of the Effect of Date Consumption on Hedonic Hunger and Appetite in Adult Individuals With Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with Type 2 diabetes and aged 19-50 years (excluding menopausal women)
- Body Mass Index (BMI) between 25 and 35 kg/m2
- Nutritional Strength Scale score of 2.5 or higher
- Agree not to start new dietary supplements or alternative therapies during the study
- Agree not to change current physical activity level and diet during the study
You will not qualify if you...
- Do not approve the volunteer consent form
- Nutritional Strength Scale score below 2.5
- Pregnant, breastfeeding, or planning pregnancy within 3 months
- Dietary energy intake less than 800 kcal/day or more than 4000 kcal/day
- Pre-diabetes, type 1 diabetes or gestational diabetes
- HbA1c greater than 10
- Taking antibiotics or hormone replacement therapy
- History of malignancy except non-melanoma skin cancer
- Regular date consumption before study
- Using insulin or oral antidiabetic drugs with thiazolidinedione
- Recent serious diabetic complications or treatments including ketoacidosis, coma, serious infections, surgery, trauma, dialysis, or serious liver or vascular conditions
- Taking medications affecting appetite such as psychotropics, antiepileptics, antidepressants, antipsychotics, or steroids
- Diagnosed eating or psychological disorders
- Physical illnesses affecting appetite or eating behavior such as uncontrolled thyroid disease, Cushing's disease, acromegaly, adrenal insufficiency, advanced chronic renal failure, tuberculosis, or HIV infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants in the intervention group consume 3 dates daily at breakfast as part of their diet. The control group does not consume dates. Participants complete questionnaires and undergo anthropometric and biochemical measurements during this period.
3 visits (at weeks 0, 6, and 12) with fortnightly diary submissions and telephone reminders for intervention group
Trial Site Locations
Total: 1 location
1
Erzurum City Hospital
Erzurum, Palandöken, Turkey (Türkiye), 25070
Actively Recruiting
Research Team
A
AYŞE ÇAMLİ
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here